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Background: Resource allocation decisions currently lack standard quantitative methods for incorporating concerns
about the worse off when analysing the cost-effectiveness of medical interventions.
Objective: To explore and demonstrate how to identify who are the worse off without a new intervention by
measuring lifetime Quality-Adjusted Life Years (QALYs) for patients across different conditions, and compare the
results to using proportional shortfall of QALYs.
Methods: Case study of eight condition-intervention pairs that are relevant to priority setting in Norway; childhood
deafness (unilateral cochlear implant), unruptured cerebral aneurysm (coiling), morbid obesity (RY gastric bypass),
adult deafness (unilateral cochlear implant), atrial fibrillation (catheter ablation), hip osteoarthritis (hip replacement),
rheumatoid arthritis (TNF inhibitor) and acute stroke (stroke unit). We extracted prospective QALYs without and with
new interventions from published health technology assessments and economic evaluations.
Results: Among the eight cases, the lifetime QALY method and the proportional shortfall method yielded
conflicting worse-off rank orders. Particularly two conditions had a substantial shift in ranking across the applications
of the two methods: childhood deafness and acute stroke. Deaf children had the lowest expected lifetime QALYs
(38.5 without a cochlear implant) and were worst off according to the lifetime approach, while patients with acute
stroke had the second-highest lifetime QALYs (76.4 without stroke units). According to proportional shortfall of
QALYs, patients with acute stroke were ranked as worse off than deaf children, which seems counterintuitive.
Conclusion: This study shows that it is feasible to identify who are the worse off empirically by the application of
lifetime QALYs and proportional shortfalls. These methods ease further examination of whether there is a true
conflict between maximization and equity or whether these two concerns actually coincide in real world cases. It is
yet to be solved whether proportional prospective health losses are more important than absolute shortfalls in
expected lifetime health in judgements about who are worse off.
Keywords: Priority setting in health, Quality-adjusted life years, Severity, Healthcare rationing, EquityBackground
Health economic evaluations and comparative effectiveness
analyses are increasingly used to inform healthcare prior-
ities [1,2]. Cost-effectiveness analysis (CEAs) with Quality-
Adjusted Life Years (QALYs) is the dominant method for
determining which health interventions maximize health
the most. The underlying assumption of such methods,
that a QALY has the same worth regardless of who gets it,
i.e. severity of illness, age, or social deprivation, is a well-
known ethical controversy [3].* Correspondence: frode.lindemark@igs.uib.no
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article, unless otherwise stated.In political philosophy, there is an extensive literature
on general arguments in favour of prioritising those who
are worse off, e.g. in terms of income, education, social
integration, opportunities, capabilities or health [3]. In
the field of health, to be worse off may refer to current
suffering or disability, expected future health losses, ex-
pected lifetime health, or simply to having the most se-
vere health problem. More precision is needed in actual
policy decision-making where large populations and op-
portunity costs are at stake. Who is worse off: Those in
worse health at the time of intervention or those who
will be in worse health if not treated, or those who will
have the worst lifetime health if not treated [4]?tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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health interventions, discrete choice experiments, policy
documents and public debate in countries like Norway,
Sweden and the Netherlands have emphasized the rele-
vance of current severity and/or expected health losses
at the time of intervention [5-10]. This particular view
gives extra weight to health gains to those with greater
current severity and expected future loss of quality and/
or length of life due to disease. In general, this position
disregards age and past loss of quality of life as relevant,
or leaves these to be treated as separate concerns [11].
In contrast, recent discrete choice studies indicate that
people’s preferences are also reflected by the view that
health gains to those with less expected total lifetime
should have priority [12,13]. This opposing view, that
health care resources should be allocated so as to reduce
inequalities in total lifetime health, is supported in previ-
ous works by Williams and Norheim and Asada [14,15].
We need a better understanding of how different views
on prioritising the worse off can be operationalised and
quantitatively integrated into models of cost-effectiveness
analysis [16,17]. Dutch researchers and policymakers have
proposed to operationalise concerns for the worse off by
adjusting the cost-effectiveness threshold according to the
proportional shortfall of QALYs caused by the condition
in question. Proportional shortfall of QALYs is a severity
measure identifying the worse off as those with the greater
current and expected health losses relative to a remaining
lifetime spent in perfect health [9,18]. Ottersen recently
provided a range of arguments for giving priority to those
with fewer lifetime QALYs [19]. In principle, a measure of
lifetime QALYs for a patient group would take into ac-
count the average health losses due to disease, both in
terms of quality of life and longevity, over the entire life-
time, and is thus a quantification of worse off with respect
to lifetime health.
In this article, we identify the worse off by measuring
lifetime QALYs and proportional shortfall of QALYs for
a realistic set of eight condition-intervention pairs with
data from published health economic evaluations, and
we illustrate how these measures offer ethically relevant
supplementary information to the effectiveness and costs
of interventions. The aim is to facilitate an explicit and
empirically based debate on the relevance of expected
lifetime health compared to other alternatives by show-
ing how different criteria would lead to different rank-
ings of conditions, and therefore, different priorities.
Methods
QALY information and definitions
QALYs are used as a generic measure of health out-
comes in health economic evaluations. A QALY can be
understood as the equivalent of one life year in perfect
health. It is the product of the time spent in a healthstate and a quality-adjustment weight ranging from 0
(death) to 1 (perfect health), reflecting people’s prefer-
ences for the health state [20].
To determine the lifetime QALYs and proportional
shortfall of QALYs for patients with a given condition
without the new intervention, we need three variables (see
Figure 1). First, the mean age of the patient group at the
time of intervention (past health). Ideally we would need
these previous life years to be quality adjusted, but we
found no studies reporting such adjustments. We there-
fore assumed that all patients had perfect health until the
time of the interventions. Second, the remaining Quality-
Adjusted Life Expectancy without the new intervention
(QALEstd, the starting point of QALEstd is the time when
the intervention starts (T)), and the ending point is the
time of death without the new intervention). Third, the
average number of remaining QALYs in absence of ill-
ness for people of the same age as the patient group
(QALEN). In addition, we report the expected QALYs
gained (QALYgain) by each intervention, which is simply
the estimated increase in QALYs by the new interven-
tion compared to standard care.
Lifetime QALYs is estimated by the sum of past health
(in this analysis we use average age of the patient group as
a proxy for past health) and average prospective health
(QALEstd) per patient. Proportional shortfall of QALYs is
estimated by calculating the expected future loss of QALYs
due to disease relative to a perfectly healthy life expect-
ancy (QALEN).
Often, QALEstd and QALYgain are discounted and gener-
ated for a shorter than lifetime horizon. QALEstd is not al-
ways reported in published CEAs, even if this is a key
output parameter in most CEA models. In this analysis,
we extracted QALEstd, QALYgain, and the mean age of the
patient group at the time of intervention from studies of
eight example cases. QALEN was taken from a Norwegian
life table (2010) unless stated otherwise. We report and
compare lifetime QALYs, QALY loss, proportional short-
fall of QALYs, and QALYgain for all example cases.
Selection of cases and search strategies
First, we selected eight condition-intervention pairs as ex-
ample cases. These cases were chosen because they 1) are
relevant to priority setting in Norway, and 2) illustrate
properties of the measures of lifetime QALYs and propor-
tional shortfall of QALYs. The condition-intervention pairs
are relevant as they differ with regard to the average age of
the patients, chronicity, impact on longevity and quality of
life, and the effectiveness, cost, and frequency of the inter-
ventions (Table 1). Deciding between them potentially in-
volves value judgments regarding whether to prioritise
younger vs. older patient groups, acute vs. chronic dis-
eases, few vs. many patients, highly effective vs. less effect-
ive interventions, and high-cost vs. low-cost interventions.
Figure 1 Representation of the QALY concept in a lifetime perspective.
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these different categories, all of which are relevant to the
fair allocation of scarce healthcare resources [21,22].
Second, we used an evidence-based approach and
searched for Health Technology Assessments (HTAs),
systematic reviews of clinical effectiveness, and cost-
effectiveness analyses for selected conditions and interven-
tions, as recommended for rapid reviews and mini-HTAs
[23,24]. An additional file shows this in more detail [see
Additional file 1]. We identified one economic evaluation
for each of the eight condition-intervention pairs from
which we extracted QALY data. Additional file 2 provides
information about the QALY construction in the source
studies. Studies that did not have information on QALEstd
were excluded from this analysis. If they were not pub-
lished, we received undiscounted data upon request
from the author of the original published study
(Table 1) [25-31].
Results
On a lifetime QALY account, the eight conditions would be
ranked from the worst-off to the best-off as follows: patients
with childhood deafness (38.5 lifetime QALYs) rheumatoid
arthritis (61.1 lifetime QALYs), adult deafness (64.0 lifetime
QALYs), atrial fibrillation (69.3 lifetime QALYs), unrup-
tured cerebral aneurysm (73.9 lifetime QALYs), morbid
obesity (76.2 lifetime QALYs), acute stroke (76.4 lifetime
QALYs), and hip osteoarthritis (82.8 lifetime QALYs)
(Figure 2).
According to the measure of lifetime QALYs, the
worst-off patients were those with a chronic condition
starting early in life, as childhood deafness, even though
deafness affects only quality of life and has no impact on
mortality. We found that patients with acute stroke –
which is generally considered a very severe disease, oftencausing both premature death and severe disability –
were comparatively better off because this group, on
average, lose QALYs late in life.
Proportional shortfall of QALYs placed childhood deaf-
ness third (proportional shortfall = 0.58), behind rheuma-
toid arthritis (proportional shortfall = 0.78) and acute
stroke (proportional shortfall = 0.60) (Figure 3). Among
the best off, patients with morbid obesity (proportional
shortfall = 0.17) were better off than patients with hip
osteoarthritis (proportional shortfall = 0.18) according to
the proportional shortfall as compared to the lifetime
QALYs approach.
Unilateral cochlear implants for childhood deafness
yielded the highest gain (10.7 QALYs), and stroke units
for acute stroke victims yielded the lowest gain (0.5
QALYs) (Figure 4).
Note especially two condition-intervention pairs in
Figure 2 through Figure 4: (A) rheumatoid arthritis/TNF
inhibitor and (B) morbid obesity/gastric bypass. Accord-
ing to both lifetime QALYs and proportional shortfall of
QALYs, A is worse off than B, whereas the gain in
QALYs is higher for B than for A. Below, we discuss why
this is ethically relevant.
Discussion
Our results confirm that it is possible to use the existing
literature to estimate lifetime QALYs and quantitatively
compare groups with different conditions to identify
who are worse off, and to compare the lifetime account
with the proportional shortfall about prospective sever-
ity. For example, we found that lifetime QALYs are lower
for childhood deafness and rheumatoid arthritis than for
acute stroke and hip osteoarthritis. A proportional short-
fall approach yields a different ranking, the main differ-
ence being that acute stroke victims become worse off,
Table 1 Condition-intervention pairs ranked in order of gain in QALYs
Patient group Age* QALEstd† QALYgain‡ Priority relevance Source References
Childhood deafness 8 30.5 10.7 (3.9) High-cost, low-volume health care intervention. To
date, relatively few patients have been considered
eligible for a cochlear implant. Cochlear implantation
has become an established routine treatment option
for profoundly deaf adults and children who do not
benefit from acoustic hearing aids both in Norway and
around the world.
HTA Bond 2009 [25]
(unilateral cochlear implant
vs hearing aid and waiting
list for implant)
Unruptured cerebral
aneurysm
50 23.9 6.4 (3.6) High-risk patient with symptomatic aneurysm produces
subarachnoid haemorrhage (SAH) with substantial
rate of mortality (30-60%) and permanent disability
(15-30%). Over the years, there has been debate about
which unruptured aneurysm to treat.
CUA Johnston 1999 [26]
(Coiling vs. no treatment)
Morbid obesity 48 28.2 5.2 (2.3) Increasing public health problem in Norway and
elsewhere. Increased risk of premature death and
reduced quality of life due to obesity-related
co-morbidities. Potential demand for bariatric surgery
is greater than availability.
HTA Klarenbach 2010 [27]
(RY gastric bypass vs. lifestyle
modification: diet and
exercise medical counselling)
Adult deafness 50 14.0 4.2 (2.4) See childhood deafness HTA Bond 2009 [25]
(Unilateral cochlear implant
implant for adult)
Atrial fibrillation 52 17.3 2.3 (1.4) Uncertainty about the intervention’s long-term effects on
stroke risk, mortality and QoL, but already established as
an attractive alternative to drug-refractory AF in
symptomatic patients with recurrent AF. Waiting list
0.5-1 year in Norway. Causes patients to pursue treatment
abroad, some at their own cost.
CUA McKenna 2009 [28]
(Catheter ablation vs.
antiarrhythmic drug therapy
Hip osteoarthritis 63 19.8 1.3 (0.9) High-volume, relatively high-cost intervention. Five
thousand hip arthroplasties per year. Half of the adult
population at risk.
CUA Rasanen 2007 [29]
(Hip replacement vs.
nonoperative approach)
Rheumatoid arthritis 55 6.1 1.3 (1.0) 20 000–30 000 patients in Norway. Lifelong burden of
pain, discomfort and physical impairment; the years of
life lost are estimated to be 5–7 years. In Norway, at
least one DMARD has to be tried before prescribing
biological agents such as TNF inhibitors on the
grounds of the higher cost of biological agents,
although combination therapy with a TNF inhibitor is
more effective in treating rheumatoid arthritis.
HTA Chen 2006 [30]
(TNF inhibition +
methotrexate vs.
Methotrexate)
Acute stroke 70 6.4 0.5 (0.3) Approximately 15 000 cases annually in Norway and is the
third most common cause of death; it is a major cause of
severe disability and accounts for a significant proportion
of healthcare spending. Over the past years, there has
been a focus on developing stroke units at hospitals
around the country.
HTA Hamidi 2010 [31]
(Stroke unit vs. general ward)
*Average age (years) at the time of intervention.
†Expected remaining quality-adjusted life years given a certain disease with standard care. Undiscounted data. Utilities expressing the current severity can be
found in Additional file 2.
‡Undiscounted data. The discounted gain in QALYs is shown in brackets. Note that the annual discount rates vary between the source studies
[see Additional file 2]. Ranking according to the discounted gains in QALYs would yield a different order.
Abbreviations: AF atrial fibrillation, CUA cost-utility analysis, DMARD disease-modifying antirheumatic drug, QoL quality of life, HTA health technology assessment,
QALY quality-adjusted life year, RY roux-en-y, TNF tumour necrosis factor.
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highly relevant for transparent and evidence-based polit-
ical discussions on how to assign higher weight to health
gains for those who are worse off.
Resources will be allocated to different patients groups,
depending on whether extra weights are given to those
who can expect to attain fewer QALYs over their lifetime
versus to those who can expect greater relative future loss
of QALYs. To our knowledge, this is the first study basedon data from published economic studies to consider the
worse off as being those with fewer lifetime QALYs, and
which compares this lifetime health approach with the
prevailing view of defining the worse off in terms of rela-
tive losses in current and future health.
Most proposed definitions of the worse off have a
future-oriented perspective [5]. The measure of lifetime
QALYs is persuasive since, in principle, absolute differ-
ences in past and future health is taken into account.
Figure 2 Ranking according to lifetime QALYs (age + QALEstd) for eight condition-intervention pairs. Childhood deafness had the worst
prognosis (top) and hip osteoarthritis had the best prognosis (bottom) from a lifetime perspective. Abbreviations: QALEstd, remaining quality-adjusted
life years given a certain disease treated with standard care; QALY, quality-adjusted life year; RY, roux-en-y; TNF, tumour necrosis factor.
Figure 3 Ranking of conditions according to proportional shortfall of QALYs. Patients with rheumatoid arthritis and acute stroke were
worst off and patients with hip osteoarthritis and morbid obesity were best off. For each condition, the total length of the bar represents the
remaining QALYs in absence of illness (QALEN). The red part of the bar represents the absolute shortfall of QALYs due to illness. Abbreviations:
QALEstd, remaining quality-adjusted life years given a certain disease treated with standard care; QALY, quality-adjusted life year; RY, roux-en-y;
TNF, tumour necrosis factor.
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Figure 4 The condition-interventions pairs ranked according to the net health gain from the intervention. Unilateral cochlear implant to
deaf children was most effective, and stroke units for acute stroke victims were least effective. Abbreviations: QALY, quality-adjusted life year; TNF,
tumour necrosis factor; RY, roux-en-y.
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vention may be relevant in judgements about who are
worse off, and it is not obvious that these concerns
should be disregarded. For example, early onset of dis-
ease is the main reason why deaf children achieve fewer
lifetime QALYs than deaf adults (annual quality of life
losses are assumed to be similar for both groups, an add-
itional table provide quality-adjustment weights) [see
Additional file 2]. Children who are born deaf will suffer
from lack of language skills throughout their entire life if
left untreated. Despite substantial prospective impair-
ment in quality of life among adults who develop pro-
found deafness, they have developed normal language
skills earlier in life, and are less prone to all of the nega-
tive lifelong effects of early deafness [32]. Consequently
there are good reasons to give higher priority to quality-
improving interventions, such as the cochlear implant,
to the deaf child than to the deaf adult. Lifetime QALYs
identifies the child as worse off. Proportional shortfall of
QALYs does not discriminate between the two groups.
Past health would have to be treated as a separate con-
cern if this was to be taken into account in the propor-
tional shortfall approach (Figures 2 and 3).
Even if deaf children will suffer from lack of language
skills their entire life, they will also, however, adapt to
their disability and learn skills required for functioning
without hearing at a younger age. The lifetime QALY ap-
proach therefore entails the same adaptation problems
as health state valuations in standard QALY applications[33]. Discrete choice techniques may adjust for adaptation
over time by obtaining health state valuations from the
general public rather than directly from patients [34].
Nevertheless, it is critical what respondents are asked in
preference elicitation studies and there is need for add-
itional empirical and normative work to fully understand
the complexities of adaptation over a lifetime [35].
Absolute shortfall of future health (QALY loss) is a
measure suggested by the UK Department of Health and
National Institute for Health and Care Excellence to be
used in weighting the societal wider impact of condi-
tions, while using proportional shortfall in weighting the
burden of illness, in value-based assessment of interven-
tions [36]. We define absolute shortfall of QALYs as the
expected future loss of QALYs from a condition, i.e. the
absolute difference between the QALY expectancy in ab-
sence of illness (QALEN) and the remaining QALYs with
standard care at the time of intervention. The lifetime
QALY approach treats lifetime QALY attainments and
lifetime QALY loss as providing the same information.
Values of these two lifetime measures are inversely cor-
related, and rank orders will not change if QALEN were
the same for all interventions.
Arrow has argued that equivalent formulations of a
choice problem should yield the same preference order
[37]. In principle, a lifetime QALY approach would
therefore yield the same preference order for both QALY
attainment and QALY shortfall if QALEN were identical
for all age groups. Nevertheless, people are typically
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people actually are less averse to QALY attainments than
equivalent QALY shortfalls over a lifetime remains un-
clear. More empirical work is needed to test preferences
of the general public on these matters.
Proportional shortfall of QALYs discriminates between
conditions with respect to relative differences in pro-
spective health. The measure identifies the worse off as
those who stand to lose the largest fraction of their
health potential [9]. The rationale appears to be that
people of all ages is entitled to fulfil the health potential
they had reason to expect in absence of illness. When
we compare the rankings of conditions according to life-
time QALYs and proportional shortfall, we find that the
proportional shortfall measure hardly discriminates be-
tween childhood deafness, adult deafness, and acute
stroke (Figure 3), despite the fact that the number of
healthy life years for these patient groups differs consid-
erably: the lifetime QALYs were 38.5, 64.0, and 76.4, re-
spectively (Figure 2). The measure of lifetime QALYs
distinguishes between conditions with respect to the in-
dividual burden of disease over the total lifetime.
We argue that underlying concerns about fair distribu-
tion of health are better captured by directing resources
towards those with fewer lifetime QALYs rather than to
those with a higher proportional shortfall of QALYs, be-
cause the former would seek to reduce inequalities in
lifetime health, while the latter would seek to reduce in-
equalities in the future health potential only [15,39].
Our results elucidate the balance between the worst
condition and the most effective intervention. Usually,
both concerns point in the same direction. For example,
among the eight cases, our results show that cochlear im-
plantation in children is the most effective intervention
and that the deaf child is also among the worst off. How-
ever, sometimes, one intervention will maximise health
and increase inequality. In the comparison between the
two condition-intervention pairs (A) rheumatoid arthritis/
TNF inhibitor and (B) morbid obesity/gastric bypass
(Figure 3), a decision to offer gastric bypass first and de-
cline to offer the TNF inhibitors would maximise average
individual health outcomes, but it would also increase the
inequality in lifetime health, and the inequality in future
health potential, between patients with rheumatoid arth-
ritis and obese patients. In cases where there is a conflict
between concerns for the worse off and the effectiveness
of the interventions, decision makers must balance com-
peting concerns or rely on fair procedures [3]. Decision
makers could give greater weight to the TNF inhibitors be-
cause of fairness considerations: patients with rheumatoid
arthritis represent the worse off group of the two.
Our study has some limitations. First, only the time
aspect of past health is captured by the method we used
to calculate lifetime QALYs. Past differences in quality isnot taken into consideration since we lack data on past
quality of life for the various conditions. Our sources, con-
ventional CEAs, start calculating QALYs at the time of
intervention. Among the eight conditions, morbid obesity
is likely to be ranked relatively higher if past suffering were
taken into account. Morbidly obese patients who are eli-
gible for surgery at the average age of 48 would probably
have suffered due to obesity and obesity-related comorbid-
ities over many years, often since adolescence or child-
hood [27]. The time elapsed between disease onset and
the time of intervention would be much shorter for
rheumatoid arthritis, atrial fibrillation, and hip osteoarth-
ritis. Knowledge about quality of life losses in this period
would result in fewer lifetime QALYs, but it is not obvious
that this would change their rankings. The inclusion of
past quality of life losses is practically challenging, and the-
oretically perhaps the most controversial implication of
the lifetime health account [19].
Second, few studies have reported lifetime QALYs, so
there is a shortage of available data. Third, the comparabil-
ity of QALY data across various studies and analytical deci-
sion models is impeded by the variations in model
structure complexity, varying time horizons, and varying
discount rates. Additional file 2 shows key model assump-
tions in the source studies. Our results are based on undis-
counted data. The discount rates used in the base cases of
the source studies differ. The reasons to discount health
outcomes at a specific rate are usually independent of the
conditions and interventions that are being assessed. There-
fore, using discounted QALY profiles may affect their rela-
tive size, and consequently our rankings, without good
reason. There are good fairness reasons to argue that a life
year in the past, present, or future should have the same
value, but there is no agreement about the role of discount-
ing [40]. We decided to include only studies that estimated
effects over a lifetime horizon. However, investigators seem
to be reluctant to pursue a lifetime analysis [see Additional
file 1]. The extrapolation of effects over a lifetime involves
uncertainty, but textbooks and guidance on health eco-
nomic evaluations generally recommend that a lifetime
horizon be applied [41]. Fourth, the validity of the results is
subject to limitations in terms of the QALY methodology.
Standard QALY calculations involve rather strong under-
lying assumptions [20]. Some uncertainty is attributed to
the quality-adjustment weights [42]. The results are prob-
ably sensitive to the quality-adjustment weights used in the
source studies [see Additional file 2]. Our approach requires
that QALYs be generated in as consistent a manner as pos-
sible. The QALY consensus group has pointed out the need
to develop a reference method for estimating QALYs [43].
Conclusion
In this study we have quantified worse-offness with re-
spect to lifetime health by measuring total lifetime QALYs,
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of QALYs to identify the worse off. Our results illustrate
that the lifetime QALY measure identifies those who stand
to attain the lower number of healthy life years over the
entire lifetime as worse off. Absolute shortfall of QALYs
yields similar results. Proportional shortfall of QALYs,
which focuses on relative current and prospective health
losses, is not sensitive to large absolute differences in ex-
pected lifetime health. The absolute measures reveals,
while the relative measure conceals, the size of the health
loss. The lifetime QALYs approach is based on the prin-
ciple of equal lifetime health. The relative shortfall ap-
proach is based on the notion that people of all ages have
a legitimate claim to fulfil their health potential. The life-
time QALYs approach challenges the prevailing view that
emphasizes prospective severity and could enhance fair
prioritisation across patient groups because it helps
identify cases where resources should be directed to-
wards interventions for those with the least expected
lifetime health.
Additional files
Additional file 1: Search strategies.
Additional file 2: Key model assumptions of source studies.
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